Instructions for Nobazit (Enisamium iodide)
Release form:
tab.cover film coating, 125 mg: 10 or 20 pcs.
tab., cover film coating, 250 mg: 10 or 20 pcs.
Description Nobazit:
Film-coated tablets, yellow, round, biconvex; in cross section, the kernel is from light yellow to yellow or yellow with a greenish tinge.
1 tab.
enisamia iodide (in terms of 100% anhydrous substance) 125 mg
Excipients : (core) lactose monohydrate (milk sugar) - 33.4 mg, microcrystalline cellulose (Vivapur 101) - 10 mg, sucrose (refined sugar) - 9 mg, povidone (low molecular weight medical polyvinylpyrrolidone or Plasdon K-17) - 3.6 mg , copovidone (plasdone S-630) - 1.4 mg, crospovidone (polyplasdone XL-10) - 3.8 mg, talc - 1.9 mg, calcium stearate - 1.9 mg.
Shell composition: Aquarius Prime BAN314047 Yellow - 6 mg (hypromellose - 3.96 mg, titanium dioxide - 1.3437 mg, capryl / caprylate (caprylic / capric triglyceride) - 0.54 mg, iron dye yellow oxide - 0.042 mg, iron dye red oxide - 0.0003 mg , dye quinoline yellow - 0.114 mg).
codes
Other antiviral drugs
Clinical and pharmacological groups Nobazit:
Antiviral and immunomodulatory drug. Interferon synthesis inductor
Active substance:
enisamia iodide
Pharmaco-therapeutic group Nobazit:
Antiviral agent
pharmachologic effect Nobazit:
Antiviral agent derived from isonicotinic acid. Effectively suppresses the action of influenza viruses and other causative agents of acute respiratory viral infections (ARVI) due to the direct (inhibitory) effect on the process of penetration of viruses through the cell membrane.
It has interferonogenic properties, increases the concentration of endogenous interferon (interferon alpha and interferon gamma) in blood plasma by 3-4 times.
Increases the body's resistance to viral infections.
Reduces acute clinical manifestations of viral intoxication, helps to reduce the duration of the disease.
Indications Nobazit
Treatment of influenza and other acute respiratory viral infections, incl. as part of complex therapy.
Method of application, course and dosage Nobazit:
Inside. The dosage regimen is individual, depending on the indications and the clinical situation.
Drug interactions Nobazit
Strengthens the effect of antibacterial and immunomodulating agents .
A combination with ascorbic acid and other vitamins is advisable .
Can be administered concurrently with recombinant interferon .
Application during pregnancy and lactation
Contraindicated for use during pregnancy and lactation (breastfeeding).
Side effect Nobazit:
Allergic reactions: hypersensitivity reactions, including skin rashes, urticaria, angioedema, itching.
On the part of the digestive system: dry and bitter taste in the mouth, edema of the oral mucosa, hypersalivation, yellowing of the tongue, nausea, vomiting, heartburn, abdominal pain, heaviness in the right hypochondrium, diarrhea, bloating.
From the respiratory system: shortness of breath, throat irritation.
In the post-registration period, in isolated cases, the following adverse reactions were noted: headache, dizziness, weakness, fluctuations in blood pressure. Contraindications for use Nobazit
An indication of a history of allergic reactions, regardless of the nature of the allergen; severe organic damage to the liver and kidneys; pregnancy; lactation period (breastfeeding); age under 18; hypersensitivity to enisamia iodide.
special instructions Nobazit:
t should be used with caution in patients with thyroid disease, especially with hyperthyroidism.
Application for impaired renal function
Not recommended for severe renal impairment.
Application for violations of liver function
Not recommended for severe liver dysfunction.
Use in elderly patients
There are no special instructions for limiting the application.
Application in children
Use in children and adolescents under the age of 18 is contraindicated.
Acute upper respiratory tract infection, unspecified
Influenza due to identified seasonal influenza virus
